These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37741273)

  • 1. Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.
    Jerusalem G; Prat A; Salgado R; Reinisch M; Saura C; Ruiz-Borrego M; Nikolinakos P; Ades F; Filian J; Huang N; Mazzei-Abba A; Tolaney SM
    Breast; 2023 Dec; 72():103580. PubMed ID: 37741273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
    Hurvitz SA; Bardia A; Quiroga V; Park YH; Blancas I; Alonso-Romero JL; Vasiliev A; Adamchuk H; Salgado M; Yardley DA; Berzoy O; Zamora-Auñón P; Chan D; Spera G; Xue C; Ferreira E; Badovinac Crnjevic T; Pérez-Moreno PD; López-Valverde V; Steinseifer J; Fernando TM; Moore HM; Fasching PA;
    Lancet Oncol; 2023 Sep; 24(9):1029-1041. PubMed ID: 37657462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
    Ma CX; Gao F; Luo J; Northfelt DW; Goetz M; Forero A; Hoog J; Naughton M; Ademuyiwa F; Suresh R; Anderson KS; Margenthaler J; Aft R; Hobday T; Moynihan T; Gillanders W; Cyr A; Eberlein TJ; Hieken T; Krontiras H; Guo Z; Lee MV; Spies NC; Skidmore ZL; Griffith OL; Griffith M; Thomas S; Bumb C; Vij K; Bartlett CH; Koehler M; Al-Kateb H; Sanati S; Ellis MJ
    Clin Cancer Res; 2017 Aug; 23(15):4055-4065. PubMed ID: 28270497
    [No Abstract]   [Full Text] [Related]  

  • 5. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
    Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
    Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
    Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
    Bidard FC; Hardy-Bessard AC; Dalenc F; Bachelot T; Pierga JY; de la Motte Rouge T; Sabatier R; Dubot C; Frenel JS; Ferrero JM; Ladoire S; Levy C; Mouret-Reynier MA; Lortholary A; Grenier J; Chakiba C; Stefani L; Plaza JE; Clatot F; Teixeira L; D'Hondt V; Vegas H; Derbel O; Garnier-Tixidre C; Canon JL; Pistilli B; André F; Arnould L; Pradines A; Bièche I; Callens C; Lemonnier J; Berger F; Delaloge S;
    Lancet Oncol; 2022 Nov; 23(11):1367-1377. PubMed ID: 36183733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
    Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhang P; Zhang Q; Tong Z; Sun T; Li W; Ouyang Q; Hu X; Cheng Y; Yan M; Pan Y; Teng Y; Yan X; Wang Y; Xie W; Zeng X; Wang X; Hu C; Geng C; Zhang H; Li W; Wu X; Zhong J; Xu J; Shi Y; Wei W; Bayaxi N; Zhu X; Xu B
    Lancet Oncol; 2023 Jun; 24(6):646-657. PubMed ID: 37182538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
    Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
    Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
    Massarweh S; Tham YL; Huang J; Sexton K; Weiss H; Tsimelzon A; Beyer A; Rimawi M; Cai WY; Hilsenbeck S; Fuqua S; Elledge R
    Breast Cancer Res Treat; 2011 Oct; 129(3):819-27. PubMed ID: 21792626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
    Xu B; Hu X; Li W; Sun T; Shen K; Wang S; Cheng Y; Zhang Q; Cui S; Tong Z; Geng C; Song E; Huang CS; Sriuranpong V; Ngan RKC; Chia YH; Wang X; Zhao H
    Eur J Cancer; 2022 Nov; 175():236-245. PubMed ID: 36155117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III
    Ma CX; Suman V; Goetz MP; Northfelt D; Burkard ME; Ademuyiwa F; Naughton M; Margenthaler J; Aft R; Gray R; Tevaarwerk A; Wilke L; Haddad T; Moynihan T; Loprinzi C; Hieken T; Barnell EK; Skidmore ZL; Feng YY; Krysiak K; Hoog J; Guo Z; Nehring L; Wisinski KB; Mardis E; Hagemann IS; Vij K; Sanati S; Al-Kateb H; Griffith OL; Griffith M; Doyle L; Erlichman C; Ellis MJ
    Clin Cancer Res; 2017 Nov; 23(22):6823-6832. PubMed ID: 28874413
    [No Abstract]   [Full Text] [Related]  

  • 16. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
    Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
    Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
    Mayer EL; Dueck AC; Martin M; Rubovszky G; Burstein HJ; Bellet-Ezquerra M; Miller KD; Zdenkowski N; Winer EP; Pfeiler G; Goetz M; Ruiz-Borrego M; Anderson D; Nowecki Z; Loibl S; Moulder S; Ring A; Fitzal F; Traina T; Chan A; Rugo HS; Lemieux J; Henao F; Lyss A; Antolin Novoa S; Wolff AC; Vetter M; Egle D; Morris PG; Mamounas EP; Gil-Gil MJ; Prat A; Fohler H; Metzger Filho O; Schwarz M; DuFrane C; Fumagalli D; Theall KP; Lu DR; Bartlett CH; Koehler M; Fesl C; DeMichele A; Gnant M
    Lancet Oncol; 2021 Feb; 22(2):212-222. PubMed ID: 33460574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
    Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
    Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
    Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.